Drug Trial Radar · NCT07646678
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Jun 15, 2031
Study completion Jun 15, 2031
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 71 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Central hypersomnia conditions are a group of sleeping disorders where the brain has trouble keeping a person awake during the day (called excessive daytime sleepiness or EDS). These conditions usually include narcolepsy (type 1 and 2) and idiopathic hypersomnia (IH). Narcolepsy type 1 (NT1) includes sudden muscle weakness while you stay awake, called cataplexy, often triggered by strong emotions. Narcolepsy type 2 (NT2) does not include cataplexy. People with narcolepsy typically feel refreshed by short naps. People with IH feel extremely sleepy during the day, and do not feel refreshed by sleep. Waking up from sleep is difficult. This is common in the morning and also when waking up from long naps. The study wants to learn about TAK-360 when taken over a long time period; this is called a long-term extension or LTE study. The main aim of this LTE study is to find out how well participants with NT1, NT2, and IH tolerate TAK-360 over a longer period (long-term tolerability) and to learn how safe TAK-360 is when given over a longer period of time (long-term safety). Participants who completed one of the TAK-360 parent studies can join this study if they meet the study rules. Parent studies include TAK-360-2001(NCT06952699), TAK-360-2002 (NCT06812078), or other TAK-360 studies that evaluate the TAK-360 medicine. All participants will receive TAK-360 in this study. They will either receive the same dose as they did in the parent study, or the closest dose available in this LTE study. Participants who received placebo (the placebo looks just like TAK-360 but does not have any medicine in it) in their parent study will receive one of the TAK-360 doses available in this study. Placebo will only be used to not reveal the dose of TAK-360 from parent studies to investigator, participants, and sponsor. Sponsor, investigators and participants will not know which TAK-360 dose was used in the LTE study as long as the parent study is ongoing. The participants will have to visit the clinic multiple times during this study.
Conditions
- Idiopathic Hypersomnia
- Narcolepsy Type 1
- Narcolepsy Type 2
Interventions
TAK-360Drug
TAK-360 tablets
PlaceboDrug
TAK-360-matching placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 5 years
Locations
33 sites in 5 countries. Site status is shown where the registry gives one.
Takeda Site 23
Chula Vista, California · Recruiting
Takeda Site 25
Santa Ana, California · Recruiting
Takeda Site 14
Colorado Springs, Colorado · Recruiting
Takeda Site 11
Brandon, Florida · Recruiting
Takeda Site 30
Miami, Florida · Recruiting
Takeda Site 7
Miami, Florida · Recruiting
Takeda Site 18
Winter Park, Florida · Recruiting
Takeda Site 6
Atlanta, Georgia · Recruiting
Takeda Site 32
Bowie, Maryland · Recruiting
Takeda Site 31
Lansing, Michigan · Recruiting
Takeda Site 21
Southfield, Michigan · Recruiting
Takeda Site 9
St Louis, Missouri · Recruiting
Takeda Site 19
Middletown, New Jersey · Recruiting
Takeda Site 24
Denver, North Carolina · Recruiting
Takeda Site 10
Huntersville, North Carolina · Recruiting
Takeda Site 22
Winston-Salem, North Carolina · Recruiting
Takeda Site 2
Cincinnati, Ohio · Recruiting
Takeda Site 4
Cincinnati, Ohio · Recruiting
Takeda Site 8
Columbia, South Carolina · Recruiting
Takeda Site 20
Austin, Texas · Recruiting
Takeda Site 3
San Antonio, Texas · Recruiting
Takeda Site 33
Norfolk, Virginia · Recruiting
Takeda Site 15
Macquarie Park, New South Wales, Australia · Recruiting
Takeda Site 12
Xicheng, Beijing Municipality, China · Recruiting
Takeda Site 5
Guangzhou, Guangdong, China · Recruiting
Takeda Site 16
Zhenzhou, Henan, China · Recruiting
Takeda Site 27
Yokohama, Kanagawa, Japan · Recruiting
Takeda Site 13
Kumamoto, Kumamoto, Japan · Recruiting
Takeda Site 29
Isahaya-shi, Nagasaki, Japan · Recruiting
Takeda Site 28
Urasoe, Okinawa, Japan · Recruiting
Takeda Site 26
Osaka, Osaka, Japan · Recruiting
Takeda Site 1
Shinjuku-ku, Tokyo, Japan · Recruiting
Takeda Site 17
Daegu, Daegu Gwang'yeogsi, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.